Corbus Pharmaceuticals Holdings Inc. Common Stock (CRBP)
Stock · NASDAQ · Health Care
$10.91as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$9.89
Industry
Biotechnology: Pharmaceutical Preparations
Fundamentals
- Market cap
- $165.27M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
How Corbus Pharmaceuticals Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2021 annual results
Source: 10-K filed Mar 8, 2022 · via SEC EDGAR / Finnhub
Corbus Pharmaceuticals Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CRBPCorbus Pharmaceuticals Holdings Inc. Common Stock$10.92▼ 1.93%Market cap $165.27MP/E —
- LFCRLifecore Biomedical Inc. Common Stock$4.58▲ 0.88%Market cap $164.67MP/E —$3.63$8.98
- OKUROnKure Therapeutics Inc. Class A Common Stock$3.78▼ 1.31%Market cap $162.39MP/E —$2.23$5.38
- TNXPTonix Pharmaceuticals Holding Corp. Common Stock$13.59▲ 0.18%Market cap $170.01MP/E —$9.4$34.04
- ARCTArcturus Therapeutics Holdings Inc. Common Stock$15.19▼ 6.06%Market cap $170.54MP/E —$5.5$24.17
- EVOEvotec SE American Depositary Shares$1.91▼ 2.80%Market cap $172.06MP/E —$3.18$7.3
- AARDAardvark Therapeutics Inc. Common Stock$5.71▼ 13.75%Market cap $154.94MP/E —$3.35$17.94
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings Inc. Common Stock | $165.27M | — | $10.92 | ▼ 1.93% | |
| LFCR Lifecore Biomedical Inc. Common Stock | $164.67M | — | $4.58 | ▲ 0.88% | $3.63$8.98 |
| OKUR OnKure Therapeutics Inc. Class A Common Stock | $162.39M | — | $3.78 | ▼ 1.31% | $2.23$5.38 |
| TNXP Tonix Pharmaceuticals Holding Corp. Common Stock | $170.01M | — | $13.59 | ▲ 0.18% | $9.4$34.04 |
| ARCT Arcturus Therapeutics Holdings Inc. Common Stock | $170.54M | — | $15.19 | ▼ 6.06% | $5.5$24.17 |
| EVO Evotec SE American Depositary Shares | $172.06M | — | $1.91 | ▼ 2.80% | $3.18$7.3 |
| AARD Aardvark Therapeutics Inc. Common Stock | $154.94M | — | $5.71 | ▼ 13.75% | $3.35$17.94 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Corbus Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; Co. To Offer And Sell Common Stock Up To $127.50M Through JefferiesBenzinga · 8/7/2026
- Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48Benzinga · 8/7/2026
- HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35Benzinga · 8/7/2026
- Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) EstimateBenzinga · 8/6/2026
- Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat ObesityBenzinga · 8/4/2026
Insider Activity
Insider Actions →Acquired
311.2K
Disposed
38.2K
- Nishant C. Saxena · August 11, 2026 · Buy2.6K @ $9.63
- Yuval Cohen · August 7, 2026 · Sale17.0K @ $10.08
- Sean F. Moran · August 7, 2026 · Sale12.0K @ $10.08
- Winston Kung · June 10, 2026 · Sale2.0K @ $7.91
- John Kenneth Jenkins · June 10, 2026 · Sale4.8K @ $7.91
- Anne Altmeyer · June 10, 2026 · Sale2.4K @ $7.91
- Nishant C. Saxena · June 3, 2026 · Buy9.0K @ $7.58
- Nishant C. Saxena · June 2, 2026 · Buy4.5K @ $7.33
- Nishant C. Saxena · May 21, 2026 · Grant192.3K
- Nishant C. Saxena · May 21, 2026 · Grant58.3K
- Winston Kung · May 19, 2026 · Grant12.3K
- Winston Kung · May 19, 2026 · Grant3.8K
- Rachelle Suzanne Jacques · May 19, 2026 · Grant12.3K
- Rachelle Suzanne Jacques · May 19, 2026 · Grant3.8K
- John Kenneth Jenkins · May 19, 2026 · Grant12.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 13.05M
- Total value held
- $121.27M
- Institutional holders
- 102
Top holders this quarter
- Unknown2.34M
- Unknown1.74M
- Unknown1.32M
- Unknown806.6K
- Unknown734.1K
- Unknown697.1K
- Unknown555.3K
- Unknown418.3K
- Unknown383.5K
- Unknown366.8K
See the full, filterable feed with live charts on the MarketWall dashboard.